Study on the Inhibitory Mechanism of Staphylococcus Aureus Leukocidin S Component LukS-PV on the Proliferation in Acute Myeloid Leukemia Cells

doi:10.3969/j.issn.1671-2587.2020.06.011

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2020, Vol. 22 ›› Issue (6): 603-609.DOI: 10.3969/j.issn.1671-2587.2020.06.011

Previous Articles Next Articles

Study on the Inhibitory Mechanism of Staphylococcus Aureus Leukocidin S Component LukS-PV on the Proliferation in Acute Myeloid Leukemia Cells

SHI Lan, XU Liang-fei, NIE Zheng-chao, et al

Department of Laboratory,the First Affiliated Hospital of University of Science and Technology of China,Hefei 230001

Received:2020-07-28 Online:2020-12-20 Published:2021-01-18

Abstract

Abstract: Objective To explore the effect of LukS-PV on the proliferation in acute myeloid leukemia (AML) cells THP-1 and HL-60 by down-regulating methyltransferase SET8.Methods Real-time fluorescence quantitative PCR (qRT-PCR) and Western blot were used to detect the expression levels of SET8 mRNA and protein in THP-1 and HL-60 cells after treatment with different concentrations of LukS-PV.The lentiviral vector with knock-down SET8 expression was transfected into THP-1 and HL-60 cells.SET8 knockdown efficiency was detected by qRT-PCR and Western blot,and the effects of SET8 knock-down on cell proliferation was detected by EdU assay.Finally,on the basis of knocking down SET8,adding LukS-PV treatment for detecting cell proliferation by EdU to explore whether LukS-PV inhibits the proliferation of leukemic cells THP-1 and HL-60 by down-regulating SET8.Results In AML cell lines THP-1 and HL-60,the expression of SET8 and H4K20me1 in LukS-PV treated group was significantly lower than that in PBS control group in a concentration-dependent manner (P<0.05).Compared with the negative control group,SET8 expression level was significantly decreased in THP-1 and HL-60 cells transfected with knock-down SET8 lentiviral (P<0.05),and cell proliferation ability showed the same trend (P<0.05).Compared with the PBS control group,knocking down SET8 could inhibit cell proliferation (P<0.05),and the inhibition of cell proliferation was more obvious when LukS-PV was added on this basis (P<0.05).Conclusion Down-regulating SET8 inhibits the proliferation of THP-1 and HL-60 AML cells,and LukS-PV can inhibit cell proliferation by down-regulating SET8 and play an anti-leukemia effect.

Key words: LukS-PV, SET8, Leukemia, Proliferation

CLC Number:

R551.3

SHI Lan, XU Liang-fei, NIE Zheng-chao, et al. Study on the Inhibitory Mechanism of Staphylococcus Aureus Leukocidin S Component LukS-PV on the Proliferation in Acute Myeloid Leukemia Cells[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(6): 603-609.

References

[1] ABDEL-WAHAB O,LEVINE R L.Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia[J].Blood,2013,121(18):3563-3572.
[2] GREENBLATT S M,NIMER S D.Chromatin modifiers and the promise of epigenetic therapy in acute leukemia[J].Leukemia,2014,28(7):1396-1406.
[3] DOMBRET H,SEYMOUR J F,BUTRYM A,et al.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts[J].Blood,2015,126(3):291-299.
[4] HE J M,XIU L,DE PORRE P,et al.Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia:results from a post hoc analysis of a randomized phase III study[J].Leuk Lymphoma,2015,56(4):1033-1042.
[5] MCCABE M T,OTT H M,GANJI G,et al.EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations[J].Nature,2012,492(7427):108-112.
[6] HARRIS W J,HUANG X,LYNCH J T,et al.The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells[J].Cancer Cell,2012,21(4):473-487.
[7] VANNINI E,PANIGHINI A,CERRI C,et al.The bacterial protein toxin,cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model[J].BMC Cancer,2014,14:449.
[8] PETERS D E,HOOVER B,CLOUD L G,et al.Comparative toxicity and efficacy of engineered Anthrax lethal toxin variants with broad anti-tumor activities[J].Toxicol Appl Pharmacol,2014,279(2):220-229.
[9] MA X L,CHANG W J,ZHANG C P,et al.Staphylococcal Panton-Valentine leukocidin induces pro-inflammatory cytokine production and nuclear factor-kappa B activation in neutrophils[J].PLoS One,2012,7(4):e34970.
[10] SPAAN A N,HENRY T,VAN Rooijen W J M,et al.The staphylococcal toxin panton-valentine leukocidin targets human C5a receptors[J].Cell Host Microbe,2013,13(5):584-594.
[11] BU S,XIE Q,CHANG W J,et al.LukS-PV induces mitochondrial-mediated apoptosis and G0/G1 cell cycle arrest in human acute myeloid leukemia THP-1 cells[J].Int J Biochem Cell Biol,2013,45(8):1531-1537.
[12] SHAN W L,BU S,ZHANG C F,et al.LukS-PV,a component of Panton-Valentine leukocidin,exerts potent activity against acute myeloid leukemia in vitro and in vivo[J].Int J Biochem Cell Biol,2015,61:20-28.
[13] DAI C Y,ZHANG C F,SUN X X,et al.LukS-PV induces differentiation by activating the ERK signaling pathway and c-JUN/c-FOS in human acute myeloid leukemia cells[J].Int J Biochem Cell Biol,2016,76:107-114.
[14] SUN X X,ZHANG S S,DAI C Y,et al.LukS-PV-regulated MicroRNA-125a-3p promotes THP-1 macrophages differentiation and apoptosis by down-regulating NF1 and bcl-2[J].Cell Physiol Biochem,2017,44(3):1093-1105.
[15] NISHIOKA K,RICE J C,SARMA K,et al.PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin[J].Mol Cell,2002,9(6):1201-1213.
[16] YANG F,SUN L Y,Li Q,et al.SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities[J].EMBO J,2012,31(1):110-123.
[17] LI Z F,NIE F,WANG S,et al.Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation[J].Proc Natl Acad Sci USA,2011,108(8):3116-3123.
[18] ZHOU H R,FU H Y,WU D S,et al.Relationship between epigenetic changes in Wnt antagonists and acute leukemia[J].Oncol Rep,2017,37(5):2663-2671.
[19] ITAHANA Y,ZHANG J Q,GÖKE J,et al.Histone modifications and p53 binding poise the p21 promoter for activation in human embryonic stem cells[J].Sci Rep,2016,6:28112.
[20] TAKAWA M,CHO HS,HAYAMI S,et al.Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression[J].Cancer research,2012,72:3217-3227.
[21] WANG C,GUO Z,WU C,LI Y,KANG S.A polymorphism at the miR-502 binding site in the 3′untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer[J].Cancer Genet,2012,205.
[22] YU N,HUANGYANG P W,YANG X H,et al.microRNA-7 suppresses the invasive potential of breast cancer cells and sensitizes cells to DNA damages by targeting histone methyltransferase SET8[J].J Biol Chem,2013,288(27):19633-19642.
[23] LIN H N,SU X Y,HE B.Protein lysine acylation and cysteine succination by intermediates of energy metabolism[J].ACS Chem Biol,2012,7(6):947-960.
[24] DAI L Z,PENG C,MONTELLIER E,et al.Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark[J].Nat Chem Biol,2014,10(5):365-370.
[25] KRIVTSOV A V,ARMSTRONG S A.MLL translocations,histone modifications and leukaemia stem-cell development[J].Nat Rev Cancer,2007,7(11):823-833.
[26] ZHANG S L,GUO Z J,XU J S,et al.miR-502-mediated histone methyltransferase SET8 expression is associated with clear cell renal cell carcinoma risk[J].Oncol Lett,2017:7131-7138.

Study on the Inhibitory Mechanism of Staphylococcus Aureus Leukocidin S Component LukS-PV on the Proliferation in Acute Myeloid Leukemia Cells

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	WANG Hui-ru, LIU Hui-lan. Factors Influencing Blood Transfusion in Patients after Unrelated Umbilical Cord Blood Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(2): 162-166.
[2]	WU Yue, ZHU Xiao-yu, LIU Hui-lan, et al. Curative Efficacy of Unrelated Donor Single-unit Umbilical Cord Blood Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(6): 627-632.
[3]	LI Gui-fang, LIU Hui-lan, GENG Liang-quan, et al. Detection and Clinical Analysis of JAK2,CALR and MPL Gene Mutations in Patients with Classical BCR-ABL1-negative Myeloproliferative Neoplasms [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(5): 537-541.
[4]	QIANG Ping, XUE Lei, WANG Min, et al.. Successful Treatment of Cytokine Release Syndrome and CAR-T Cell-related Encephalopathy Syndrome: A Report of Two Cases and Literature Review [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(4): 413-419.
[5]	ZHAO Xing-yun, BIAN Mao-hong. Advances in Research on Relationship between MicroRNAs and Erythroid Growth, Proliferation, Differentiation and Apoptosis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(4): 445-448.
[6]	SHEN Ji-min, LIU Xin, WANG Xing-bing. Effects of TLR-3 Agonists Combined with TLR-9 Agonists on Cell Morphology and Immunophenotype of Dendritic Cells [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(1): 71-76.
[7]	LI Yan-Xiang, DI Yu-Wei, CHEN Qian-li, et al. The Effect of Leukemia Cells on K⁺ and Glucose Detection in Peripheral Blood [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(6): 641-645.
[8]	WU Jin-ju, GUO Qing, LIU Xin, et al. The Impact of Bortezomib and Idarubicin Therapy on Calreticulin Expression and Apoptosis of Acute Myeloid Leukmia Cells [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(5): 502-505.
[9]	WANG Yuan-yuan, LI Li, LIU Fang-fang. Expression of Endometrial LIF and LIFR in Women with Primary Infertility [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(2): 166-169.
[10]	LI Li, CUI Cheng-Hua, XU Jian-Ning, et al. Clinical and Laboratory Characteristics of the Patients with Leukemia t（11;19）（q23;p13） [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(1): 87-92.
[11]	SUN Shao-qin. A Therapeutic Effect of Recombinant Thrombopoietin on Thrombocytopenia Caused by Leukemia Chemotherapy [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(6): 632-634.
[12]	MALi-li,WANG Wei-guo,and ZHANG Xia et al.. Clinical Significance of Five Coagulation Markers in Patients with Acute Promyelocytic Leukemia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2018, 20(4): 425-427.
[13]	ZHENG WEI-wei, LV CHANG-kun, ZHANG WEN-jing. Mechanism of Triptolide Induced Apoptosis of Acute Myelogenous Leukemia Stem Cells [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2017, 19(6): 540-542.
[14]	XU Rui-qin, HU Ke-ni. The Application Value of Acute Leukemia Minimal Residual Disease with Bone Marrow Biopsy Detecting [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2017, 19(1): 79-82.
[15]	PAN Qing, PENG Jing, SUN Xiao-xi, DAI Chun-yang, MA Xiao-ling, et al. The Expression and Significance of MiR-125a-3p in Peripheral Blood of Patients with Acute Myeloid Leukemia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2016, 18(2): 127-130.